文献速递胸部肿瘤放疗放疗物理与技术

NIELS试验不均一剂量递增放疗的设计与试验前剂量计划质量保证

Design and pre-trial dose planning quality assurance of the Nordic trial of inhomogeneous dose escalated radiotherapy for patients with limited disease small cell lung cancer: NIELS.
PubMed 文献 · Radiother Oncol · 2025-05-21

NIELS试验将比较局限期小细胞肺癌标准放疗(60 Gy/40次,每日两次)与不均一剂量递增放疗(至80 Gy/40次,每日两次)能否改善总生存。本研究将5例代表性病例分发至7个北欧中心进行试验前剂量计划QA,发现所有靶区均可递增超过标准剂量,GTVp和GTVn中位平均剂量分别为79.6 Gy和75.8 Gy,35份递增计划中观察到3次强制性OAR约束违反,结论为多中心条件下不均一剂量递增可行且可遵守OAR约束。

要点

  • 所有靶区均可递增超过标准剂量,GTVp中位平均剂量79.6 Gy,GTVn为75.8 Gy。
  • 部分靶区因邻近OAR未能完全递增,35份递增计划中观察到3次强制性OAR约束违反。
  • 标准与递增计划的平均肺剂量有统计学差异但临床很小,心脏和食管平均剂量无差异。

核心结论

  • NIELS试验设计的不均一剂量递增在多中心条件下可行,且递增可遵守OAR约束。

研究设计与样本

  • NIELS试验将局限期小细胞肺癌患者随机分配至标准剂量放疗(60 Gy/40次,每日两次)或不均一剂量递增放疗(至80 Gy/40次,每日两次)。
  • 试验前QA将5例代表性病例分发至7个北欧中心,每例制定标准和递增剂量计划。

主要发现

  • 所有靶区均可递增超过标准剂量,GTVp中位平均剂量79.6 Gy(76.9-81.0),GTVn中位平均剂量75.8 Gy(68.3-81.1)。
  • 部分靶区因邻近OAR未能完全递增。
  • 35份递增剂量计划中观察到3次强制性OAR约束违反。
  • 标准与递增计划平均肺剂量有统计学差异但临床很小,患者间中位差异0.3 Gy。
  • 心脏和食管平均剂量无差异。

关键数值与推荐

  • 递增靶区为原发肿瘤(GTVp)和受累淋巴结(GTVn)。
  • 标准剂量放疗为60 Gy/40次,每日两次;递增放疗至平均剂量80 Gy/40次,每日两次。

临床怎么用

  • 在多中心开展局限期小细胞肺癌不均一剂量递增放疗前,应进行试验前剂量计划QA以评估可行性和OAR约束遵守情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The NIELS trial will examine if inhomogeneous dose-escalated radiotherapy up to a mean dose of 80 Gy in 40 fractions (fx), twice-daily delivered (BID), for patients with limited disease small cell lung cancer can improve overall survival. Because of the inherent risks of dose-escalation, pre-trial QA is particularly important. This study aims to examine the feasibility of the NIELS trial planning approach in a multicenter setting. MATERIALS AND METHODS: The NIELS trial will randomize patients between standard dose radiotherapy (60 Gy/40fx BID) and inhomogeneous dose-escalated radiotherapy (up to 80 Gy/40fx BID). Five representative patient cases were distributed to seven Nordic centers for pre-trial QA planning of a standard and an escalated dose plan. Targets for escalation were primary tumor (GTVp) and involved lymph nodes (GTVn). We evaluated inter-center variation in achievable dose-escalation and doses to organs at risk (OAR). RESULTS: All targets could be escalated beyond the standard dose, with a median mean dose of 79.6 Gy [76.9-81.0] and 75.8 Gy [68.3-81.1] for GTVp and GTVn. Some targets could not be fully escalated due to OAR proximity. Three separate breaches of mandatory OAR constraints were observed in 35 escalated dose plans. There was a statistical difference in mean lung dose between standard and escalated plans, though clinically small, with a median inter-patient difference of 0.3 Gy. There were no differences in mean doses to the heart and esophagus. CONCLUSION: Inhomogeneous dose-escalation as planned in the NIELS trial is feasible, and the dose-escalation can be performed respecting the OAR constraints in a multi-center setting.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Linde S, Møller DS, Linaa MB, et al. Design and pre-trial dose planning quality assurance of the Nordic trial of inhomogeneous dose escalated radiotherapy for patients with limited disease small cell lung cancer: NIELS. Radiother Oncol. 2025. PMID: 40409366. doi:10.1016/j.radonc.2025.110946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。